Observational study on breast sarcoma characteristics and outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multi-institutional retrospective study aims to identify key clinical features and treatment strategies for patients with breast sarcoma, a rare type of soft tissue tumor. Data will be collected from patients referred to participating institutions between January 2000 and June 2020, focusing on their clinical history and outcomes. The study seeks to address the lack of specific prospective trials in this area by analyzing existing medical data to inform better management and treatment principles for breast sarcomas.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \>18 years at diagnosis
* primary or secondary breast sarcoma
* availability of medical data needed for the study (histopathological data, surgery, chemotherapy, including preceding chemotherapeutic regimens for secondary breast sarcomas, radiation therapy)

Exclusion Criteria:

* sarcoma metastases to the breast
* chest wall sarcomas not arising in the mammary gland
* cutaneous sarcomas

Where it's running

• Fondazione del Piemonte per l'Oncologia IRCC Candiolo
  Candiolo, Torino, Italy Recruiting
• Azienda Ospedaliera S. Orsola-Malpighi
  Bologna, Bo, Italy Not yet recruiting
• Istituto Europeo di Oncologia
  Milan, Mi, Italy Not yet recruiting
• Istituto Clinico Humanitas
  Rozzano, Mi, Italy Not yet recruiting
• Azienda Ospedaliera Universitaria Paolo Giaccone
  Palermo, PA, Italy Not yet recruiting
• Centro di Riferimento Oncologico - Unit of Medical Oncology
  Aviano, Pordenone, Italy Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lurbinectedin plus irinotecan for advanced desmoplastic small round cell tumor

  This study will try lurbinectedin combined with irinotecan in people 15 and older whose desmoplastic small round cell tumor has come back or spread after anthracycline chemotherapy.

  Recruiting at 6 sites Phase 2 Italian Sarcoma Group · Candiolo, Torino and 10 other locations · NCT07328425

• Observational study of localized angiosarcoma

  This study is trying to find the best ways to treat localized angiosarcoma by looking at how patients are managed across different hospitals in Italy.

  Recruiting at 12 sites Italian Sarcoma Group · Rozzano, Milano and 18 other locations · NCT06375941

• Observational study of localized osteosarcoma characteristics and treatments

  This study is looking at the characteristics and treatments of people with localized osteosarcoma to see how well current therapies work and to help improve future care.

  Recruiting at 15 sites Italian Sarcoma Group · Aviano, Pordenone and 15 other locations · NCT04890067

• Observational study on Ewing's sarcoma of the bone

  This study is collecting information from patients with Ewing's sarcoma to learn more about the disease and improve treatment options.

  Recruiting at 17 sites Italian Sarcoma Group · Rozzano, MI and 18 other locations · NCT04845893

• Evaluating Trabectedin for Advanced Leiomyosarcoma

  This study is testing if a drug called Trabectedin can help people with advanced leiomyosarcoma feel better and live longer compared to another treatment called Gemcitabine.

  Recruiting at 15 sites Phase 2 Italian Sarcoma Group · Bologna, BO and 16 other locations · NCT04383119

• Using Trabectedin for Advanced Mesenchymal Chondrosarcoma

  This study is testing if a drug called trabectedin can help people aged 16 and older with advanced mesenchymal chondrosarcoma that has gotten worse after previous treatment.

  Recruiting at 6 sites Phase 2 Italian Sarcoma Group · Prato, Firenze and 6 other locations · NCT04305548

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.